Current trials with immune therapy take advantage of CD40 agonism in different ways, such as an adenoviral vector vaccine encoding TAA MUC1 and CD40-ligand in multiple advanced adenocarcinomas (172), or TriMixDC-Mel-IPI, a monocyte-derived dendritic cell encoding multiple melanoma TAAs as well as CD70, CD40 ligand, and TLR4 (173). The gene discussed is CD40LG; the disease is adenocarcinoma.